Lilly, Incyte?s Olumiant Cuts Recovery Time When Added to Veklury in Hospitalized COVID-19 Patients
Eli Lilly and Incyte reported Monday that the JAK1/JAK2 inhibitor Olumiant (baricitinib) in combination with Gilead Sciences? Veklury (remdesivir) met the primary endpoint of the ACTT 2 study by significantly reducing the time to recovery compared to Veklury alone in hospitalized patients with COVID-19. Eli Lilly said that based on the results, it plans to discuss the potential for emergency-use authorisation (EUA) of Olumiant with the FDA, as well as similar measures with other regulatory bodies.
The study, which was launched in May by the US National Institute of Allergy and Infectious Diseases (NIAID), included 1,034 patients and evaluated a 4-mg oral dose of Olumiant plus intravenous Veklury, versus Veklury alone, in hospitalized patients infected with SARS-CoV-2 who show signs of lung involvement, such as the need for supplemental oxygen or mechanical ventilation, or having abnormal chest X-rays. The primary endpoint was time to recovery, with recovery defined as the patient no longer being hospitalized at day 29, or being well enough for discharge because they either do not need supplemental oxygen anymore or ongoing medical care in hospital.